In patients undergoing Cardiopulmonary Bypass (CPB) with extracorporeal circulation, the rapid restoration of blood flow to the ischemic tissue induces cardiac damage termed as myocardial Ischemic Reperfusion (I/R) injury.
Background
The severity of reactions following major surgeries, such as Coronary Artery Bypass Graft Surgery (CABG) under Cardiopulmonary Bypass (CPB) is comparable with Systemic Inflammatory Response Syndrome (SIRS). During Ischemic/Reperfusion (I/R) injury, the release of proinflammatory factors is exacerbated. In addition to the inflammatory response during CABG, these patients have a chronic state of inflammation, which is due to coexisting disease, such as atherosclerosis (1) (2) (3) . Several known in-jurious factors, such as hypothermia, hemodilution, electrolyte imbalance, and transfusion initiate systemic stress response in cardiac surgeries. However, among them, reperfusion and cardioplegic arrest are the main known injurious factors (4) . A number of anti-inflammatory agents, including Vitamins C and E, statins, Colchicine, Steroids, and micro-nutrients, such as Selenium and Zinc, have been studied previously (5) (6) (7) (8) (9) . However, inflammatory reactions still occur and result in significant post-surgery complications, such as delirium, acute kidney injury, myocardial infarction, coma, stroke, cognitive dysfunction, which Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited translate to long-term hospitalization, prolonged recovery, higher mortality rate, and cost burden on the society (10-12). Therefore, identifying safe and effective agents with limiting stress response properties is vital. The sympathetic system activation is linked to the mentioned stress response and results in increased level of epinephrine and consequently higher myocardial oxygen consumption rate. Thus, theoretically, any anesthetic agent with reducing sympathetic flow properties could have cardioprotective effects. DEX, as an alpha 2 receptor agonist, with analgesics and anxiolytic effects, has been considered to be beneficial in the setting of cardiac surgery (13) (14) (15) (16) . To the best of the author's knowledge, a few studies have investigated its cardioprotective effects in cardiac surgery, particularly on-pump patients. In addition, it has been declared that the achieved data are contrary and more work is indicated (12).
Objectives
The aim of the present trial was to explore whether DEX administration was associated with cardioprotective effects in patients undergoing CABG surgery. To test this hypothesis, creatinine kinase-MB (CKMB) and cardiac troponin I (CTnI) were measured.
Methods
Firstly, the study protocol was approved by the Research Ethics Committee of Guilan University of Medical Sciences (Ref: 95022129) and was registered in Iranian Registry of Clinical Trial (IRCT) with the following code: IR.GUMS.REC.1395.46.
The study was performed at Dr. Heshmat Hospital, a university and referral centre affiliated to GUMS in Rasht, Iran. From April 2016 to March 2017, all eligible patients were enrolled in the trial. Informed consent was obtained from all participants.
Inclusion criteria: Patients aged 30 to 65 years old, with American Society of Anesthesiologists (ASA) class I and II, who were undergoing isolated elective CABG surgery using CPB and three vessel disease, were included in the study.
Exclusion Criteria
Those requiring re-do and emergency surgery, or Left Ventricular Ejection Fraction (LVEF) < 40%, patients with recent myocardial infarction or stroke, Heart Rate (HR) < 50 times/minute, a preoperative systolic pressure < 90 mmHg, renal dysfunction (serum creatinine level > 2.0 mg/dL), uncontrolled diabetes, thyroid disease, pregnancy, major trauma during the recent three months, and patients, who were not able to give an informed consent, were excluded from the study.
Sample Size
Based on a margin of error, α = 0.05 and β = 10%, an expected power of 90% and a Z value of 1.28, the suitable sample size for this study was determined as 55 patients in each group.
Randomization and Blinding
By using randomized fixed quadripartite blocks, the patients were allocated to either DEX group (D) or control group (C) with an equal chance. The patient and the independent investigators, who recorded the date were blinded to the groups. However, the anesthesiologist knew the patients' groups, to deal with the probable adverse effects.
Intervention
The surgery team was the same in both groups and anesthesia was provided, according to the standard protocol of the hospital. The standard practice for DEX administration recommends a loading dose of 1 µg/kg within more than ten minutes and 0.2 to 0.7 µg/kg/hour for maintenance. However, in order to prevent significant hemodynamic changes, it is not always routinely performed. Studies have shown that hypotension and bradycardia, induced by DEX, often occur with loading dose or maintenance of more than 0.7 µg/kg/hour (12) . In this study, considering the use of Propofol and Sufentanil to prevent bradycardia and hypotension, the dose of DEX was lower than the average applied dosage. Patients in the intervention group received an infusion of 0.3~0.5 µg/kg/hour DEX just before induction of anesthesia until 24 hours at the Intensive Care Unit (ICU). Patients in the control group received normal saline as placebo in the same manner. Blood samples were taken to measure CTnI and CK-MB levels at five time points, including baseline and 6 ,12, 24 and 48 hours after the surgery (T 0 -T 4 ). CKMB and CTnI serum level measurements were performed at the clinical chemistry laboratory by an employed expert lab technician. Firstly, 5 mL of venous blood samples were taken and then plasma was separated by centrifugation at 1200 g for 10 minutes. An immuneinhibition assay and auto-analyzer Hitachi 912 were used to measure CKMB concentrations. The technique for recording CTnI values was the Enzyme-Linked Immunosorbent Sandwich Assay (ELISA) (BioTek-ELX800).
Patients in both groups received propofol and the target dose as 4 µg/mL was according to the Bispectral Index (BIS) values, which were kept between 45 and 55. Sufentanil was infused at the induction dose of 0.5 to 1 µg/kg. Enough relaxation for tracheal intubation was achieved with 0.1 mg/kg Pancuronium, and during the surgery, one-third of the initial dose was used.
Statistical Analysis
Data analysis was performed using SPSS Statistical Software, version 16.0 (SPSS Inc, Chicago, Ill., USA). To compare the categorical variables between two groups, the Chi-square test was applied. K-S test, which was followed by parametric tests was used to describe the normality of the variables. Comparing the parametric data at five time points was performed by repeated measurement test and independent t-test to determine the parametric data between groups. Data were presented as mean ± SD and P value < 0.05 were considered as statistically significant.
Results
In this study, 121 eligible patients were divided to treatment and control groups. In group D, intra-aortic balloon pump was used for two cases and in group C, three patients were not extubated within the expected time and two underwent valvar repair during the operation. Finally, data from 114 cases were analyzed (Figure 1 ). The mean age of patients in groups D and C were 55.55 ± 6.74 and 56.46 ± 5.96 years, respectively (P = 0.446). No significant difference was found between the two groups regarding the baseline characteristics, details of surgery, and also cardiovascular risk factors and patients' medication (Tables  1 and 2 ). Baseline serum levels of CKMB (P = 0.686) and CTnI (P = 0.25) showed no significant difference as well. In both groups, CPB caused a marked increase in CKMB and CTnI plasma concentrations compared with baseline (P = 0.0001). Serum CKMB levels increased from 2.27 ± 0.59 to 7.81 ± 1.39 and 2.22 ± 0.64 to 7.46 ± 1.25, and CTnI levels from 10.22 ± 0.17 to 4.89 ± 1.1 and 0.27 ± 0.28 to 4.5 ± 1.4 in groups C and D, respectively (P = 0.0001). According to CKMB, there was a significant difference between the two groups at T 2 (P = 0.002) and T 3 (P = 0.0001) and based on CTnI at T 2 (P = 0.004) and T 3 (P = 0.0001). However, no significant difference was observed at the other measurement time points (Table 3 ) (Figures 2 and 3) . However, no significant difference was observed at the other measurement time points. No adverse effect was recorded due to this intervention. 
Discussion
In general, CABG is the most effective approach in patients with coronary artery stenosis. However, I/R injury results in inflammatory cytokines release and cardiac damage (17, 18) . The current study was planned following promising studies, establishing the safety and efficacy of DEX in CABG patients. Furthermore, DEX can induce positive effects during intra and post-operation period by decreasing heart rate and blood pressure. Consequently, post-surgical oxygen demand decreases as well. Thus, keeping the balance between myocardial oxygen supply and demand is facilitated. In addition, following DEX administration, Cyclic Adenosine Monophosphate (CAMP) level is increased and coronary vasodilation occurs, which results in myocardial ischemia risk reduction (13, (19) (20) (21) (22) . The conventional surgical approach has the potential to cause tissue damage, which represents as elevated cardiac enzymes, such as CKMB and CTnI that are known indexes of myocardial damage during I/R injury (4) . It is well known that these enzymes have a prognostic role and higher survival rate in patients with normal values of these enzymes compared with those above the threshold levels (23) (24) (25) (26) . Bulow et al. (20) in a clinical trial, supported the current study by reporting that DEX could be an important anesthetic agent in CABG surgery. Their inflammatory indexes were Interleukin IL 1 , IL 6 and Tumour Necrosis Factor (TNF)α. The difference between the two methods should be considered. Firstly, they enrolled patients, who were scheduled for CABG under mini pump; obviously, the severity of stress response is less than the use of CPB. Sedighine- sia and continued until extubation. It was shown that the results in the DEX group was significantly better, according to ventilation time, neurologic events, delirium, and AKI. Jalonen et al. (28) reported that administration of DEX 0.5 µg/kg/minute before induction of anesthesia and 0.7 µg/kg/minute as maintenance had no beneficial effects (31) (32) (33) (34) . In this research, on-pump CABG patients were evaluated, which could be the strength of the study, as this groups has not been studied extensively in previous studies. However, according to the exclusion criteria, higher risk patients were not enrolled. It is not clear if they could benefit from this intervention or tolerate it.
Suggestions
Obviously, a better understanding of the main triggers of inflammatory reactions during CABG helps find the optimal dosage, onset time, infusion duration, and case selection to achieve meaningful results. Future well-planned and standard clinical trials on different types of surgical interventions are welcome.
Limitation
This study had a few limitations. First, it was a single center trial with a small sample size. Second, other post-operative major adverse cardiovascular, events such as arrhythmias, were not recorded. In fact, more variables should be measured to answer this question. Third, the multiplicity of unknown triggers for cardiac enzyme release, might cause false diagnosis. Forth, due to limited follow up time, long-term outcomes were not observed. Fifth, the infusion time was restricted, starting intraoperatively and lasing up to 24 hours post operation. Thus, the effects of prolonged infusion were not understood.
Conclusions
In CABG patients, perioperative DEX, as an anesthetic adjuvant, could reduce cardiac injury and significant reductions in mortalities. Of course, more work on antiinflammatory properties of DEX, are required before this strategy is routinely recommended in clinical practice.
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